Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study
- 23 October 2020
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 123 (1) , 252-260
Abstract
Introduction: Hepatic artery infusion pump (HAIP) chemotherapy is a specialized therapy for patients with unresectable colorectal liver metastases (uCRLM). Its effectiveness was demonstrated from a high volume center, with uncertainty regarding the feasibility and safety at other centers. Therefore, we sought to assess the safety and feasibility of HAIP for the management of uCRLM at other centers.Methods: We conducted a multicenter retrospective cohort study of patients with uCRLM treated with HAIP from January 2003 to December 2017 at six North American centers initiating the HAIP program. Outcomes included the safety and feasibility of HAIP chemotherapy.Results: We identified 154 patients with HAIP insertion and the median age of 54 (48–61) years. The burden of disease was >10 intra‐hepatic metastatic foci in 59 (38.3%) patients. Patients received at least one cycle of systemic chemotherapy before HAIP insertion. Major complications occurred in 7 (4.6%) patients during their hospitalization and 13 (8.4%) patients developed biliary sclerosis during follow‐up. A total of 148 patients (96.1%) received at least one‐dose of HAIP chemotherapy with a median of 5 (4–7) cycles. 78 patients (56.5%) had a complete or partial response and 12 (7.8%) received a curative liver resection.Conclusion: HAIP programs can be safely and effectively initiated in previously inexperienced centers with good response.Keywords
This publication has 36 references indexed in Scilit:
- Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal CarcinomaJournal of Clinical Oncology, 2009
- The role of floxuridine in metastatic liver diseaseMolecular Cancer Therapeutics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741Journal of Clinical Oncology, 2008
- Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy FailureAnnals of Surgical Oncology, 2007
- Technical Complications and Durability of Hepatic Artery Infusion Pumps for Unresectable Colorectal Liver Metastases: An Institutional Experience of 544 Consecutive CasesJournal of the American College of Surgeons, 2005
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology, 2003
- Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastasesEuropean Journal of Surgical Oncology, 2000
- Hepatic Arterial Infusion of Chemotherapy after Resection of Hepatic Metastases from Colorectal CancerNew England Journal of Medicine, 1999